Hong Kong · Delayed Price · Currency is HKD Gaush Meditech Statistics
Total Valuation
Gaush Meditech has a market cap or net worth of HKD 683.68 million. The enterprise value is 770.98 million.
| Market Cap | 683.68M |
| Enterprise Value | 770.98M |
Important Dates
The next estimated earnings date is Thursday, June 4, 2026.
| Earnings Date | Jun 4, 2026 |
| Ex-Dividend Date | Jun 23, 2025 |
Share Statistics
Gaush Meditech has 143.33 million shares outstanding. The number of shares has decreased by -1.83% in one year.
| Current Share Class | 143.33M |
| Shares Outstanding | 143.33M |
| Shares Change (YoY) | -1.83% |
| Shares Change (QoQ) | -1.21% |
| Owned by Insiders (%) | 45.13% |
| Owned by Institutions (%) | 0.29% |
| Float | 48.06M |
Valuation Ratios
The trailing PE ratio is 6.47.
| PE Ratio | 6.47 |
| Forward PE | n/a |
| PS Ratio | 0.45 |
| PB Ratio | 0.36 |
| P/TBV Ratio | 1.51 |
| P/FCF Ratio | 5.06 |
| P/OCF Ratio | 4.26 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 3.43, with an EV/FCF ratio of 5.70.
| EV / Earnings | 7.20 |
| EV / Sales | 0.50 |
| EV / EBITDA | 3.43 |
| EV / EBIT | 6.15 |
| EV / FCF | 5.70 |
Financial Position
The company has a current ratio of 2.40, with a Debt / Equity ratio of 0.30.
| Current Ratio | 2.40 |
| Quick Ratio | 1.33 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | 2.51 |
| Debt / FCF | 4.18 |
| Interest Coverage | 5.75 |
Financial Efficiency
Return on equity (ROE) is 5.55% and return on invested capital (ROIC) is 5.07%.
| Return on Equity (ROE) | 5.55% |
| Return on Assets (ROA) | 2.71% |
| Return on Invested Capital (ROIC) | 5.07% |
| Return on Capital Employed (ROCE) | 5.18% |
| Weighted Average Cost of Capital (WACC) | 3.79% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 893 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 2.22 |
Taxes
In the past 12 months, Gaush Meditech has paid 26.14 million in taxes.
| Income Tax | 26.14M |
| Effective Tax Rate | 20.48% |
Stock Price Statistics
The stock price has decreased by -21.42% in the last 52 weeks. The beta is 0.02, so Gaush Meditech's price volatility has been lower than the market average.
| Beta (5Y) | 0.02 |
| 52-Week Price Change | -21.42% |
| 50-Day Moving Average | 5.26 |
| 200-Day Moving Average | 7.40 |
| Relative Strength Index (RSI) | 38.66 |
| Average Volume (20 Days) | 64,640 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gaush Meditech had revenue of HKD 1.54 billion and earned 107.04 million in profits. Earnings per share was 0.74.
| Revenue | 1.54B |
| Gross Profit | 695.36M |
| Operating Income | 125.31M |
| Pretax Income | 127.62M |
| Net Income | 107.04M |
| EBITDA | 197.80M |
| EBIT | 125.31M |
| Earnings Per Share (EPS) | 0.74 |
Balance Sheet
The company has 487.03 million in cash and 564.36 million in debt, with a net cash position of -77.33 million or -0.54 per share.
| Cash & Cash Equivalents | 487.03M |
| Total Debt | 564.36M |
| Net Cash | -77.33M |
| Net Cash Per Share | -0.54 |
| Equity (Book Value) | 1.89B |
| Book Value Per Share | 13.11 |
| Working Capital | 701.54M |
Cash Flow
In the last 12 months, operating cash flow was 160.50 million and capital expenditures -25.34 million, giving a free cash flow of 135.17 million.
| Operating Cash Flow | 160.50M |
| Capital Expenditures | -25.34M |
| Depreciation & Amortization | 66.13M |
| Net Borrowing | n/a |
| Free Cash Flow | 135.17M |
| FCF Per Share | 0.94 |
Margins
Gross margin is 45.27%, with operating and profit margins of 8.16% and 6.97%.
| Gross Margin | 45.27% |
| Operating Margin | 8.16% |
| Pretax Margin | 8.31% |
| Profit Margin | 6.97% |
| EBITDA Margin | 12.88% |
| EBIT Margin | 8.16% |
| FCF Margin | 8.80% |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 5.77%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 5.77% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 41.35% |
| Buyback Yield | 1.83% |
| Shareholder Yield | 7.60% |
| Earnings Yield | 15.66% |
| FCF Yield | 19.77% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gaush Meditech has an Altman Z-Score of 1.41 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.41 |
| Piotroski F-Score | 5 |